Serendex Pharmaceuticals A/S : Major shareholding notification from Serendex’ major shareholders cf. sections 27(1) and 29(1)(3) of the Danish Securities Trading Act

Pursuant to the Danish Securities Trading Act sections 27(1) and 29(1)(3) Serendex is subject to the disclosure of the following recieved information:

BioPharma Holding ApS has announced a share transaction decreasing their shareholding of Serendex shares by 228.700 shares equivalent to 1.52% of the the total share capital and voting rights. Following the transaction BioPharma Holding ApS' shareholding is below 5% of the share capital and the voting rights.

Serendex Pharmaceuticals Major shareholding notification from Serendex' major shareholders

Meddelelse i henhold til Værdipapirhandelsloven §29

For further information, please contact:
Kim Arvid Nielsen, CEO Mobile [phone] E-mail: [e-mail]